The collected data from the Zurich Registry for pulmonary Hypertension (PH) are evaluated in a retrospective analysis. This study examines the number of patients and their exact diagnoses who are treated at the University Hospital of Zurich and potentially other participating in the Zurich Registry. Other demographic parameters such as age, gender and body-mass-index are also part of the evaluation. Furthermore, the analysis will focus on the newest guidelines on PH. Therefore, it will be checked how many patients would fulfill the therapeutic goals in terms of New York Heart Classification (NYHA), 6-minute walk distance, sign of right heart failure and N-terminal pro-brain-natriuretic peptide(NTproBNP). Additionally, the study examines on how the patients are treated. Despite the different kind of Drugs, the focus lies on the combination therapy (single, double, triple) and the impact the therapy had on the patients.
Study Type
OBSERVATIONAL
Enrollment
313
Respiratory Clinic, University Hospital of Zurich
Zurich, Switzerland
Change in NYHA/WHO functional class
Change of the functional class over time in relation to given vasodilator treatment
Time frame: Baseline, 3 months, 6 months, 1 year
Change in 6 minute walk distance
Change of the 6 minute walk distance over time in relation to given vasodilator treatment
Time frame: Baseline, 3 months, 6 months, 1 year
Change in NT-proBNP
Change of the 6 minute walk distance over time in relation to given vasodilator treatment
Time frame: Baseline, 3 months, 6 months, 1 year
Percentage of patients that are in NYHA/WHO functional class <= II
Percentage of patients that are in NYHA/WHO functional class \<= II will be assessed at respective timepoints
Time frame: Baseline, 3 months, 6 months, 1 year
Percentage of patients with a 6 minute walk distance > 440m
Percentage of patients with a 6 minute walk distance \> 440m will be assessed at respective timepoints
Time frame: Baseline, 3 months, 6 months, 1 year
Percentage of patients with a NT-proBNP < 300 ng/l
Percentage of patients with a NT-proBNP \< 300 ng/l will be assessed at respective timepoints
Time frame: Baseline, 3 months, 6 months, 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.